What is the ROE (Return on Equity) of Ucb this year?
The ROE of Ucb this year is 0.04 undefined.
Ucb ROE 2024
Ucb ROE
0.04
Ticker
UCB.BR
ISIN
BE0003739530
WKN
852738
In 2024, Ucb's return on equity (ROE) was 0.04, a -17.13% increase from the 0.05 ROE in the previous year.
Ucb Aktienanalyse
What does Ucb do?
The company UCB SA is a Belgian pharmaceutical company that was founded in 1928 and is now active worldwide. The business model of UCB SA is based on the discovery and development of medications for severe diseases. The core competencies of the company are in neurology, immunology, and cardiology. In the history of UCB SA, there are several milestones. In 1961, UCB SA succeeded in synthesizing antihistamines, which marked the beginning of the development of medications for allergic diseases. In the 1990s, UCB SA began to focus on the development of medications for the treatment of epilepsy and Parkinson's disease. In the 2000s, UCB SA acquired several companies, expanding its portfolio of medications and its geographic reach. The company operates three different divisions: pharmaceuticals, biopharmaceuticals, and specialty chemicals. In the pharmaceuticals division, UCB SA develops and distributes medications for the treatment of epilepsy, Parkinson's disease, and autoimmune diseases such as rheumatoid arthritis and lupus. UCB SA's biopharmaceutical division focuses on researching antibodies for the treatment of various diseases such as cancer and multiple sclerosis. In the specialty chemicals division, UCB SA produces chemical products such as solvents and paints. The company offers a wide range of products tailored to the needs of patients with various diseases. One example of a well-known product from UCB SA is Keppra, a medication for the treatment of epilepsy. Keppra is one of the most prescribed medications for epilepsy and has helped improve the lives of millions of patients. Another example is Cimzia, a medication for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Cimzia belongs to a new generation of medications that aim to selectively influence the immune system and thus inhibit inflammation. UCB SA places great value on innovation and constantly researches new medications and therapies. The company has a strong research and development team with over 3,000 employees and invests approximately 25% of its revenue annually in the research and development of new medications. Overall, UCB SA is an innovative and successful pharmaceutical company with a broad portfolio of medications and a strong commitment to the quality of the products developed. The company is dedicated to improving the lives of patients with severe diseases and remains a key player in the global pharmaceutical industry in the long term. Ucb ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Ucb's Return on Equity (ROE)
Ucb's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Ucb's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Ucb's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Ucb’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Ucb stock
How has the Return on Equity (ROE) of Ucb developed compared to the previous year?
The ROE of Ucb has increased by -17.13% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Ucb?
A high ROE indicates that Ucb generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Ucb?
A low ROE can indicate that Ucb is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Ucb affect the company?
A change in ROE (Return on Equity) of Ucb can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Ucb?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Ucb?
Some factors that can influence Ucb's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Ucb pay?
Over the past 12 months, Ucb paid a dividend of 1.33 EUR . This corresponds to a dividend yield of about 0.82 %. For the coming 12 months, Ucb is expected to pay a dividend of 1.36 EUR.
What is the dividend yield of Ucb?
The current dividend yield of Ucb is 0.82 %.
When does Ucb pay dividends?
Ucb pays a quarterly dividend. This is distributed in the months of May, May, May, May.
How secure is the dividend of Ucb?
Ucb paid dividends every year for the past 26 years.
What is the dividend of Ucb?
For the upcoming 12 months, dividends amounting to 1.36 EUR are expected. This corresponds to a dividend yield of 0.84 %.
In which sector is Ucb located?
Ucb is assigned to the 'Health' sector.
Wann musste ich die Aktien von Ucb kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Ucb from 4/30/2024 amounting to 1.36 EUR, you needed to have the stock in your portfolio before the ex-date on 4/26/2024.
When did Ucb pay the last dividend?
The last dividend was paid out on 4/30/2024.
What was the dividend of Ucb in the year 2023?
In the year 2023, Ucb distributed 1.3 EUR as dividends.
In which currency does Ucb pay out the dividend?
The dividends of Ucb are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Ucb
Our stock analysis for Ucb Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ucb Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
